Korea Research Institute of Bioscience and Biotechnology
发明人:
申请号：
EP18781754.9
公开号：
EP3594242A1
申请日:
2018.04.05
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to a fusion protein for cancer treatment and a use thereof.The fusion protein for preventing or treating cancer of the present invention comprises a fusion polypeptide comprising: an antibody or fragment thereof binding to a tumor-associated antigen； a linker； and a NK cell-inducing protein of CXCL16, wherein a co-administration of the fusion polypeptide along with the NK cells, an immunocyte therapeutic agent, greatly increases an influx of the NK cells into cancer expressing a certain antigen, thereby having a remarkable effect on preventing or treating cancer.
